In vivo chondroprotection and metabolic synergy of glucosamine and chondroitin sulfate

Clinical Orthopaedics and Related Research

Volumn 381, Issue , 2000, Pages 229-240

  Lippiello, Louis ^a,c   Woodward, John ^a   Karpman, Robert ^a   Hammad, Tarek A ^b  

^a MARICOPA MEDICAL CENTER   (United States)

^b NUTRAMAX LABORATORIES INC   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHONDROITIN SULFATE; CHONDROPROTECTIVE AGENT; COSAMIN DS; ENZYME; FCHG 49; GLUCOSAMINE; GLUCOSAMINE DERIVATIVE; GLYCOSAMINOGLYCAN; GLYCOSAMINOGLYCAN PEPTIDE; GLYCOSAMINOGLYCAN POLYSULFATE; HYALURONIC ACID; HYLAGAN; MANGANESE ASCORBATE; MANGANESE DERIVATIVE; PENTOSAN POLYSULFATE; TRH 122; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARTILAGE DEGENERATION; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE SEVERITY; DRUG POTENTIATION; ENZYME INHIBITION; FEMUR CONDYLE; GLYCOSAMINOGLYCAN METABOLISM; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; RABBIT; TREATMENT OUTCOME;

EID: 0033653572     PISSN: 0009921X     EISSN: 15281132     Source Type: Journal    
DOI: 10.1097/00003086-200012000-00027     Document Type: Article

References (47)

1. The influence of the route of administration on the bioavailability of an endogenous macromolecule: Chondroitin sulfate (CSA)
2. Analysis of glycosaminoglycans in human serum after oral administration of chondroitin sulfate
3. Stimulation of proteoglycan production by glucosamine sulfate in chondrocytes isolated from osteoarthritic articular cartilage in vitro
4. An assay for total hexosamine and differential assay for glucosamine and galactosamine
5. Chondroprotective agents: Glucosamine salts and chondroitin sulfates
6. Scintigraphic evaluation of dogs with acute synovitis after treatment with glucosamine hydrochloride and chondroitin sulfate
7. Biochemistry and pharmacokinetic aspects of oral treatment with chondroitin sulfate
8. Glucosamine sulphate for the management of arthrosis: A controlled clinical investigation
9. Synthesis of cartilage matrix by mammalian chondrocytes in vitro. III. Effects of ascorbate
10. Nutraceuticals as therapeutic agents in osteoarthritis
11. Amelioration of lapine osteoarthritis by treatment with glycosaminoglycan-peptide associated complex (rumalon)
12. Body size and metabolic rate: Exponent and coefficient of the allometric equation. The role of units
13. Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue
14. Drugs for osteoarthrosis. II. The effects of a glycosaminoglycan polysulphate ester (Arteparon) on proteoglycan aggregation and loss from articular cartilage of immobilized rabbit knee joints
15. Oral treatment with a glucosamine-chondroitin sulfate compound for degenerative joint disease in horses: 25 cases
16. Experimental osteoarthritis in rabbits
17. Treating osteoarthritis with chondroprotective agents
18. Changes in chondroitin sulfate concentration in rabbit blood plasma depending on the method of its administration
19. Pentosan polysulfate (cartrophen) prevents the hydrocortisone injected loss of hyaluronic acid and proteoglycans from cartilage of rabbit joints
20. Glucosamine, chondroitin and manganese ascorbate for degenerative joint disease of the knee or low back: A randomized, double-blind placebo-controlled pilot study
21. Determination of the nutraceutical, glucosamine hydrochloride in raw materials, dosage forms and plasma using pre-column derivatization with ultraviolet HPLC
22. Arthroscopic evaluation of potential structure modifying activity of hyaluronan (Hyalgan) in osteoarthritis of the knee
23. Bioavailability of oral chondroitin sulfate
24. Biochemical and metabolic aspects of osteoarthrosis
25. Biochemical and metabolic abnormalities in articular cartilage from osteoarthritic human hips. II. Correlation of morphology with biochemical and metabolic data
26. Biochemical and metabolic abnormalities in articular cartilage from osteoarthritic human hips. III. Distribution and metabolism of amino sugar-containing macromolecules
27. Biochemical and metabolic abnormalities in articular cartilage from osteoarthritic human hips
28. Uridine diphosphate xylosyltransferase activity in cartilage from manganese-deficient chicks
29. Use of enzymatically isolated chondrocytes for short term metabolic studies
30. Comparison of the anti-inflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis
31. Experimentally induced degenerative joint lesions following partial meniscectomy in the rabbit
32. Anti-inflammatory activity of chondroitin sulfate
33. Recommendations for the Registration of Drugs Used in the Treatment of Osteoarthritis
34. A method for judging all contrasts in the analysis of variance
35. Profile of glucosamine sulfate as an example of slow acting drug in osteoarthritis. 18(th) Congress Rheumatology
36. Pharmacokinetics of glucosamine in man
37. Method of histomorphometric assessment of GAG in articular cartilage
38. Effects of acidity, cations and alcoholic fractionation on absorption of heparin from the gastrointestinal tract
39. One year changes in hind limb kinematics, general reaction forces and knee stability in an experimental model of OA
40. Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: A pilot study
41. Protective effect of exogenous chondroitin 4,6-sulfate in the acute degradation of articular cartilage in the rabbit
42. Chondroitin sulfate SYSMOAD (structure/disease modifying anti-osteoarthritis drug) in the treatment of finger joint OA
43. Stimulation of matrix formation in rabbit chondrocyte cultures by ascorbate. 1. Effect of ascorbate analogs and beta aminopropionitrile
44. Metabolic study on chondroitin sulfates in rabbits
45. Reduction of the severity of canine osteoarthritis by prophylatic treatment with oral doxycycline